June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Clinical outcome of central serous chorioretinopathy with or without choroidal neovascularization
Author Affiliations & Notes
  • AYA KAMIMURA
    Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan
  • Akiko Miki
    Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan
  • Maya Kishimoto
    Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan
  • Wataru Matsumiya
    Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan
  • Hisanori Imai
    Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan
  • Sentaro Kusuhara
    Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan
  • Makoto Nakamura
    Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan
  • Footnotes
    Commercial Relationships   AYA KAMIMURA None; Akiko Miki None; Maya Kishimoto None; Wataru Matsumiya None; Hisanori Imai None; Sentaro Kusuhara Bayer, Code F (Financial Support), Novartis, Code F (Financial Support), Clinigen, Code F (Financial Support), Novartis, Code R (Recipient), Bayer, Code R (Recipient), Eisai, Code R (Recipient), Abbvie, Code R (Recipient); Makoto Nakamura None
  • Footnotes
    Support  No
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3807 – F0228. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      AYA KAMIMURA, Akiko Miki, Maya Kishimoto, Wataru Matsumiya, Hisanori Imai, Sentaro Kusuhara, Makoto Nakamura; Clinical outcome of central serous chorioretinopathy with or without choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3807 – F0228.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the 2- year outcome of half-time photodynamic therapy (htPDT) in chronic central serous chorioretinopathy (cCSC) with or without choroidal neovascularization (CNV)

Methods : This was a retrospective study of 88 eyes from 88 patients with cCSC who underwent htPDT and were followed up for more than 24 months. Patients were divided into two groups with (21 eyes) or without (67 eyes) CNV before htPDT treatment. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and resolution and recurrence of subretinal fluid (SRF) were evaluated at baseline and 1, 3, 6, 12, and 24 months after PDT.

Results : There was a significant difference in age between the two groups (P < 0.01). A significant improvement in the BCVA was found at all time points in eyes without CNV but only at 24 months after htPDT in eyes with CNV. There were significant differences in BCVA between groups at any time points. CRT was significantly reduced in both groups at all time points with no significant intergroup differences. A significant reduction in the SCT was found at all time points in the eyes without CNV, but only at 1 and 24 months after htPDT in the eyes with CNV. There were significant differences between groups in the rate of recurrent and persistent SRF (P=0.013 and P=0.017, respectively). Multivariate analysis revealed that the presence of CNV was significantly associated with recurrence and persistence of SRF after initial PDT (P=0.012 and P=0.023, respectively). Logistic regression analysis showed that baseline BCVA, not the presence of CNV, was significantly associated with BCVA at 24 months after initial PDT (P<0.01).

Conclusions : A htPDT for cCSC was less effective in eyes with CNV than without CNV regarding the recurrence and the persistence of SRF. Additional treatment might be required in eyes with CNV during 24-months follow-up periods.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×